IL29066A - Pharmaceutical preparations containing multi-chain poly-nucleotides to encourage interferon production in humans, animals or cell cultures - Google Patents

Pharmaceutical preparations containing multi-chain poly-nucleotides to encourage interferon production in humans, animals or cell cultures

Info

Publication number: IL29066A
Authority: IL; Israel
Prior art keywords: interferon; rna; acid; compositions according; animals
Prior art date: 1966-12-23

Application number

IL2906667A

Other languages

English (en)

Hebrew (he)

Original Assignee

Merck & Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1966-12-23

Filing date

1967-12-05

Publication date

1972-11-28

1967-12-05 Application filed by Merck & Co Inc filed Critical Merck & Co Inc

1972-11-28 Publication of IL29066A publication Critical patent/IL29066A/en

Links

102000014150 Interferons Human genes 0.000 title claims description 146
108010050904 Interferons Proteins 0.000 title claims description 146
229940079322 interferon Drugs 0.000 title claims description 127
241001465754 Metazoa Species 0.000 title claims description 59
108091033319 polynucleotide Proteins 0.000 title claims description 30
102000040430 polynucleotide Human genes 0.000 title claims description 30
239000002157 polynucleotide Substances 0.000 title claims description 30
238000004113 cell culture Methods 0.000 title claims description 24
230000001939 inductive effect Effects 0.000 title claims description 20
230000015572 biosynthetic process Effects 0.000 title claims description 13
239000008194 pharmaceutical composition Substances 0.000 title claims 2
229920002477 rna polymer Polymers 0.000 claims description 62
229920000642 polymer Polymers 0.000 claims description 58
241000700605 Viruses Species 0.000 claims description 53
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 49
238000000034 method Methods 0.000 claims description 36
239000000126 substance Substances 0.000 claims description 34
210000004027 cell Anatomy 0.000 claims description 32
239000002253 acid Substances 0.000 claims description 29
239000000203 mixture Substances 0.000 claims description 28
238000002360 preparation method Methods 0.000 claims description 25
208000015181 infectious disease Diseases 0.000 claims description 19
241001136494 Talaromyces funiculosus Species 0.000 claims description 16
239000001963 growth medium Substances 0.000 claims description 14
241001480512 Mammalian orthoreovirus 3 Species 0.000 claims description 12
210000002845 virion Anatomy 0.000 claims description 12
230000002401 inhibitory effect Effects 0.000 claims description 11
238000004519 manufacturing process Methods 0.000 claims description 10
238000002347 injection Methods 0.000 claims description 9
239000007924 injection Substances 0.000 claims description 9
230000003362 replicative effect Effects 0.000 claims description 9
241000282414 Homo sapiens Species 0.000 claims description 6
238000011084 recovery Methods 0.000 claims description 6
241000282412 Homo Species 0.000 claims description 5
230000000536 complexating effect Effects 0.000 claims description 5
238000010253 intravenous injection Methods 0.000 claims description 5
239000007788 liquid Substances 0.000 claims description 5
108091034057 RNA (poly(A)) Proteins 0.000 claims description 4
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 4
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 4
241001493065 dsRNA viruses Species 0.000 claims description 4
210000004102 animal cell Anatomy 0.000 claims description 3
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 3
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 3
150000001720 carbohydrates Chemical class 0.000 claims description 3
210000005260 human cell Anatomy 0.000 claims description 3
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 claims description 2
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims description 2
235000015097 nutrients Nutrition 0.000 claims description 2
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
230000004936 stimulating effect Effects 0.000 claims description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims 2
230000002070 germicidal effect Effects 0.000 claims 2
AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 claims 1
229930183912 Cytidylic acid Natural products 0.000 claims 1
241000450599 DNA viruses Species 0.000 claims 1
GRSZFWQUAKGDAV-UHFFFAOYSA-N Inosinic acid Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-UHFFFAOYSA-N 0.000 claims 1
235000010716 Vigna mungo Nutrition 0.000 claims 1
244000042295 Vigna mungo Species 0.000 claims 1
239000013543 active substance Substances 0.000 claims 1
IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 claims 1
IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 claims 1
229940028843 inosinic acid Drugs 0.000 claims 1
235000013902 inosinic acid Nutrition 0.000 claims 1
239000004245 inosinic acid Substances 0.000 claims 1
241000283973 Oryctolagus cuniculus Species 0.000 description 65
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 42
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 36
239000000243 solution Substances 0.000 description 32
241000699670 Mus sp. Species 0.000 description 30
230000000694 effects Effects 0.000 description 28
210000002966 serum Anatomy 0.000 description 28
230000006698 induction Effects 0.000 description 26
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
239000002799 interferon inducing agent Substances 0.000 description 24
102000006382 Ribonucleases Human genes 0.000 description 23
108010083644 Ribonucleases Proteins 0.000 description 23
102000004142 Trypsin Human genes 0.000 description 22
108090000631 Trypsin Proteins 0.000 description 22
239000012588 trypsin Substances 0.000 description 22
241000894007 species Species 0.000 description 21
102000039446 nucleic acids Human genes 0.000 description 19
108020004707 nucleic acids Proteins 0.000 description 19
150000007523 nucleic acids Chemical class 0.000 description 19
239000011780 sodium chloride Substances 0.000 description 18
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
230000003287 optical effect Effects 0.000 description 16
230000035945 sensitivity Effects 0.000 description 16
238000012360 testing method Methods 0.000 description 16
238000011282 treatment Methods 0.000 description 16
239000000872 buffer Substances 0.000 description 15
241000711975 Vesicular stomatitis virus Species 0.000 description 14
238000007792 addition Methods 0.000 description 14
239000002585 base Substances 0.000 description 14
238000011534 incubation Methods 0.000 description 14
229940047124 interferons Drugs 0.000 description 14
241000699666 Mus <mouse, genus> Species 0.000 description 13
238000000605 extraction Methods 0.000 description 13
239000000411 inducer Substances 0.000 description 13
229910000162 sodium phosphate Inorganic materials 0.000 description 13
230000009385 viral infection Effects 0.000 description 13
229920005654 Sephadex Polymers 0.000 description 12
239000012507 Sephadex™ Substances 0.000 description 12
239000011777 magnesium Substances 0.000 description 12
239000000463 material Substances 0.000 description 12
239000001488 sodium phosphate Substances 0.000 description 12
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 12
230000003612 virological effect Effects 0.000 description 12
210000003734 kidney Anatomy 0.000 description 11
210000003292 kidney cell Anatomy 0.000 description 11
239000002244 precipitate Substances 0.000 description 11
230000009467 reduction Effects 0.000 description 11
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
238000004587 chromatography analysis Methods 0.000 description 10
230000016396 cytokine production Effects 0.000 description 9
239000008363 phosphate buffer Substances 0.000 description 9
230000004083 survival effect Effects 0.000 description 9
240000004808 Saccharomyces cerevisiae Species 0.000 description 8
238000000862 absorption spectrum Methods 0.000 description 8
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
230000015556 catabolic process Effects 0.000 description 8
238000006731 degradation reaction Methods 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
239000010410 layer Substances 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
102000040650 (ribonucleotides)n+m Human genes 0.000 description 7
102000016911 Deoxyribonucleases Human genes 0.000 description 7
108010053770 Deoxyribonucleases Proteins 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
230000000120 cytopathologic effect Effects 0.000 description 7
239000000284 extract Substances 0.000 description 7
238000002955 isolation Methods 0.000 description 7
239000002773 nucleotide Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
241000588724 Escherichia coli Species 0.000 description 6
241000711941 Murine orthopneumovirus Species 0.000 description 6
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 6
102000005891 Pancreatic ribonuclease Human genes 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
239000001913 cellulose Substances 0.000 description 6
229920002678 cellulose Polymers 0.000 description 6
238000005119 centrifugation Methods 0.000 description 6
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
210000001161 mammalian embryo Anatomy 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
230000007505 plaque formation Effects 0.000 description 6
229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 6
238000000746 purification Methods 0.000 description 6
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 5
241000196324 Embryophyta Species 0.000 description 5
208000036142 Viral infection Diseases 0.000 description 5
239000012153 distilled water Substances 0.000 description 5
238000010438 heat treatment Methods 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
230000010512 thermal transition Effects 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
241000233866 Fungi Species 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 4
241000702263 Reovirus sp. Species 0.000 description 4
230000008859 change Effects 0.000 description 4
238000012512 characterization method Methods 0.000 description 4
210000003837 chick embryo Anatomy 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000006196 drop Substances 0.000 description 4
230000002538 fungal effect Effects 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000002609 medium Substances 0.000 description 4
239000008188 pellet Substances 0.000 description 4
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
239000000047 product Substances 0.000 description 4
239000001509 sodium citrate Substances 0.000 description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
239000012064 sodium phosphate buffer Substances 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
239000001226 triphosphate Substances 0.000 description 4
229930024421 Adenine Natural products 0.000 description 3
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
229960000643 adenine Drugs 0.000 description 3
239000013043 chemical agent Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
UFJPAQSLHAGEBL-RRKCRQDMSA-N dITP Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(N=CNC2=O)=C2N=C1 UFJPAQSLHAGEBL-RRKCRQDMSA-N 0.000 description 3
238000004925 denaturation Methods 0.000 description 3
230000036425 denaturation Effects 0.000 description 3
238000002156 mixing Methods 0.000 description 3
-1 nucleotide diphosphates Chemical class 0.000 description 3
239000011734 sodium Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
239000011800 void material Substances 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
235000010469 Glycine max Nutrition 0.000 description 2
108010008488 Glycylglycine Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
229940122618 Trypsin inhibitor Drugs 0.000 description 2
101710162629 Trypsin inhibitor Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
230000009102 absorption Effects 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000000287 crude extract Substances 0.000 description 2
229940104302 cytosine Drugs 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-N dCTP Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO[P@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-N 0.000 description 2
230000034994 death Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000001177 diphosphate Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
238000002270 exclusion chromatography Methods 0.000 description 2
238000000855 fermentation Methods 0.000 description 2
230000004151 fermentation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
229940043257 glycylglycine Drugs 0.000 description 2
239000000413 hydrolysate Substances 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000004400 mucous membrane Anatomy 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002674 ointment Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
150000002972 pentoses Chemical class 0.000 description 2
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
238000006116 polymerization reaction Methods 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
108020004418 ribosomal RNA Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000004062 sedimentation Methods 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000007921 spray Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000012085 test solution Substances 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
235000011178 triphosphate Nutrition 0.000 description 2
239000002753 trypsin inhibitor Substances 0.000 description 2
238000002211 ultraviolet spectrum Methods 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
HZLHRDBTVSZCBS-UVJJDBRNSA-N 4-[(e)-(4-aminophenyl)-(4-imino-3-methylcyclohexa-2,5-dien-1-ylidene)methyl]-2-methylaniline;hydrochloride Chemical compound Cl.C1=CC(=N)C(C)=C\C1=C(C=1C=C(C)C(N)=CC=1)/C1=CC=C(N)C=C1 HZLHRDBTVSZCBS-UVJJDBRNSA-N 0.000 description 1
241000711404 Avian avulavirus 1 Species 0.000 description 1
101100328886 Caenorhabditis elegans col-2 gene Proteins 0.000 description 1
108090000565 Capsid Proteins Proteins 0.000 description 1
102100023321 Ceruloplasmin Human genes 0.000 description 1
241000282552 Chlorocebus aethiops Species 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000712431 Influenza A virus Species 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
206010024264 Lethargy Diseases 0.000 description 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000702244 Orthoreovirus Species 0.000 description 1
208000033952 Paralysis flaccid Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
241000702632 Rice dwarf virus Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000723873 Tobacco mosaic virus Species 0.000 description 1
241000608278 Una virus Species 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
241000702661 Wound tumor virus Species 0.000 description 1
239000011358 absorbing material Substances 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
239000000061 acid fraction Substances 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000005273 aeration Methods 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000013019 agitation Methods 0.000 description 1
239000003513 alkali Substances 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
210000001691 amnion Anatomy 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
238000013096 assay test Methods 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
NKQIMNKPSDEDMO-UHFFFAOYSA-L barium bromide Chemical compound [Br-].[Br-].[Ba+2] NKQIMNKPSDEDMO-UHFFFAOYSA-L 0.000 description 1
229910001620 barium bromide Inorganic materials 0.000 description 1
159000000009 barium salts Chemical class 0.000 description 1
239000011324 bead Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
244000309466 calf Species 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
238000012754 cardiac puncture Methods 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
239000012930 cell culture fluid Substances 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000009918 complex formation Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
239000013530 defoamer Substances 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
230000003544 deproteinization Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
235000006694 eating habits Nutrition 0.000 description 1
238000010828 elution Methods 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
239000003885 eye ointment Substances 0.000 description 1
208000028331 flaccid paralysis Diseases 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000002402 hexoses Chemical group 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000000215 hyperchromic effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
201000009240 nasopharyngitis Diseases 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000000424 optical density measurement Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
238000000053 physical method Methods 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
238000002962 plaque-reduction assay Methods 0.000 description 1
238000012809 post-inoculation Methods 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical class [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
OABGXCSOGYJCPE-UHFFFAOYSA-N propan-2-ol;hydrate;hydrochloride Chemical compound O.Cl.CC(C)O OABGXCSOGYJCPE-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229940121649 protein inhibitor Drugs 0.000 description 1
239000012268 protein inhibitor Substances 0.000 description 1
230000006920 protein precipitation Effects 0.000 description 1
239000010453 quartz Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000012465 retentate Substances 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000002002 slurry Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
235000011006 sodium potassium tartrate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000005979 thermal decomposition reaction Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
230000024275 uncoating of virus Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)

IL2906667A 1966-12-23 1967-12-05 Pharmaceutical preparations containing multi-chain poly-nucleotides to encourage interferon production in humans, animals or cell cultures IL29066A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US60413766A	1966-12-23	1966-12-23
US64111967A	1967-05-25	1967-05-25
US65930867A	1967-08-09	1967-08-09
US68493667A	1967-11-22	1967-11-22

Publications (1)

Publication Number	Publication Date
IL29066A true IL29066A (en)	1972-11-28

Family

ID=27505067

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL2906667A IL29066A (en)	1966-12-23	1967-12-05	Pharmaceutical preparations containing multi-chain poly-nucleotides to encourage interferon production in humans, animals or cell cultures

Country Status (7)

Country	Link
BE (1)	BE708470A (de)
DE (1)	DE1617659C3 (de)
FR (2)	FR1605535A (de)
GB (1)	GB1187830A (de)
IE (1)	IE31924B1 (de)
IL (1)	IL29066A (de)
NL (1)	NL159282B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2092875A1 (en) *	1970-06-26	1972-01-28	Maes Roland	Interferon stimulants - dialkylaminoalkyl dextran-nucleic acid comple
EP0063657A1 (de) *	1981-04-29	1982-11-03	Merck & Co. Inc.	Topische Anwendung von Interferon-Induktoren
GB2216416B (en) *	1988-03-11	1992-06-24	Sandoz Ltd	Nucleobase source for the stimulation of the immune system
US5624912A (en) *	1991-08-21	1997-04-29	Burcoglu; Arsinur	Method of treating HIV infection and related secondary infections with defibrotide
AU692433B2 (en) *	1993-01-13	1998-06-11	Arsinur Burcoglu	Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1046770A (en) *	1963-05-14	1966-10-26	James Harrison Stanton	Therapeutic composition containing mycelial matter

1967
- 1967-12-05 IL IL2906667A patent/IL29066A/en unknown
- 1967-12-05 IE IE147367A patent/IE31924B1/xx unknown
- 1967-12-15 GB GB5707967A patent/GB1187830A/en not_active Expired
- 1967-12-21 DE DE19671617659 patent/DE1617659C3/de not_active Expired
- 1967-12-22 NL NL6717585A patent/NL159282B/xx not_active IP Right Cessation
- 1967-12-22 FR FR133660A patent/FR1605535A/fr not_active Expired
- 1967-12-22 BE BE708470D patent/BE708470A/xx unknown
1968
- 1968-03-22 FR FR144921A patent/FR8373M/fr not_active Expired

Also Published As

Publication number	Publication date
IE31924B1 (en)	1973-02-21
FR8373M (de)	1971-02-22
NL6717585A (de)	1968-06-24
DE1617659A1 (de)	1971-04-01
NL159282B (nl)	1979-02-15
IE31924L (en)	1968-06-23
FR1605535A (en)	1979-02-23
BE708470A (de)	1968-06-24
GB1187830A (en)	1970-04-15
DE1617659B2 (de)	1981-05-21
DE1617659C3 (de)	1982-01-21

Publication	Publication Date	Title
Lampson et al.	1967	Inducers of interferon and host resistance. I. Double-stranded RNA from extracts of Penicillium funiculosum.
US4124702A (en)	1978-11-07	Polynucleotides active as inducers of interferon production in living animal cells
Field et al.	1967	Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes.
US4130641A (en)	1978-12-19	Induction of interferon production by modified nucleic acid complexes
SenGupta et al.	1989	Activation of interferon-regulated, dsRNA-dependent enzymes by human immunodeficiency virus-1 leader RNA
FI72124B (fi)	1986-12-31	Foerfarande foer tillvaratagande av interferon
Damme et al.	1989	Identification by sequence analysis of chemotactic factors for monocytes produced by normal and transformed cells stimulated with virus, double‐stranded RNA or cytokine
Kudo et al.	1965	Synthesis of reovirus ribonucleic acid in L cells
US4216203A (en)	1980-08-05	Process for producing interferon
JP4617058B2 (ja)	2011-01-19	コンセンサスインターフェロンのＢ型肝炎表面抗原とｅ抗原の抑制剤としての応用
US4163780A (en)	1979-08-07	Ks-2-a
JP2005508848A6 (ja)	2005-08-04	コンセンサスインターフェロンのＢ型肝炎表面抗原とｅ抗原の抑制剤としての応用
FI72143C (fi)	1987-04-13	Foerfarande foer framstaellning av maenniskointerferon.
IL29066A (en)	1972-11-28	Pharmaceutical preparations containing multi-chain poly-nucleotides to encourage interferon production in humans, animals or cell cultures
US3629235A (en)	1971-12-21	Process for isolating an interferon inducer and the product per se
Fantes	1970	Interferons: purification and physicochemical aspects
EP0048283A1 (de)	1982-03-31	Virushemmende verbindung und verfahren zu deren herstellung
US3843629A (en)	1974-10-22	Complexs of polyriboinosinic acid and polyribo-2-thiocytidylic acid
US4480032A (en)	1984-10-30	Natural mixture of Type I and Type II interferons
US3660564A (en)	1972-05-02	Interferon induction
US3775398A (en)	1973-11-27	N-oxide of double stranded rna
JP2001517715A (ja)	2001-10-09	ヘルペスおよび関連ウイルス感染症の治療用の組成物、および該組成物を含む医薬製剤
US4213970A (en)	1980-07-22	Antiviral compositions containing a transfer-ribonucleic acid
Kanoh et al.	1968	Pyrogenic principle of the ribonucleic acid from the yeast Candida utilis
SU897099A3 (ru)	1982-01-07	Способ получени вещества кS-2-а,обладающего противоопухолевым и антимикробным действием